Actavis (ACT) PT Lifted to $345 at Guggenheim Following Q4 Results and Update
Tweet Send to a Friend
Guggenheim analyst Louise Chen reiterated a Buy rating and raised her price target on Actavis (NYSE: ACT) to $345.00 (from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
